Jpmorgan Chase & CO Fulgent Genetics, Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Fulgent Genetics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 338,044 shares of FLGT stock, worth $6.61 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
338,044
Previous 158,567
113.19%
Holding current value
$6.61 Million
Previous $3.11 Million
136.0%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding FLGT
# of Institutions
201Shares Held
16.1MCall Options Held
2.04MPut Options Held
14K-
Black Rock Inc. New York, NY3.92MShares$76.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.45MShares$28.3 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.27MShares$24.8 Million0.01% of portfolio
-
Dimensional Fund Advisors LP Austin, TX1.11MShares$21.6 Million0.01% of portfolio
-
State Street Corp Boston, MA794KShares$15.5 Million0.0% of portfolio
About Fulgent Genetics, Inc.
- Ticker FLGT
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 30,265,800
- Market Cap $592M
- Description
- Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions...